Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Phase 2/3 OV company Genelux trades at US$35.00

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Jun 20, 2023 2:01pm

157 Views

Post# 35505700

RE:RE:RE:RE:RE:Phase 2/3 OV company Genelux trades at US$35.00

I think many of us investors feel a little short changed at this point, particularly in light of how Matt pumped the next '6-9 months' back in November. The lack of positive news and movement brings on insecurities and angst.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it